#evaluate(de(' #AdditionalMetaTags# '))#
Healiva is a patient-centric Biotech commercialising a portfolio of innovative, personalised and affordable life-enhancing precision medicine for chronic and acute wounds and target key pain-points in the patient care pathway. The end-to-end approach has core enzyme technology and is paired with cell therapies or medical devices. A successful regimen can prevent bone infection, hospitalisation, amputation and even death – allowing patients to re-establish their normal life routines.
Healiva aims to become a “one stop shop” B2B wound care solutions provider with a multifaceted customer base encompassing hospitals, medical practitioners, insurance providers and patients.
Venture Briefing Lugano: Unlocking the secrets of entrepreneurship with Priyanka Dutta-Passecker, CEO & founder of Healiva (venturelab.swiss)
Venture Leaders Biotech 2022: Captain’s blog by Recolony CEO Ana Montalban-Arques (venturelab.swiss)
The Venture Leaders Biotech impress international investors and industry leaders in Boston (venturelab.swiss)
Healiva: The Venture Leader Biotech offering end-to-end wound care solutions (venturelab.swiss)
The Venture Leaders Biotech 2022 kick-off their roadshow to Boston and Cambridge (venturelab.swiss)